Share this article

The Centre de Cancérologie de la Porte de Saint-Cloud (CCPSC) in Boulogne, France, has initiated treatments with a non-invasive brain tumour therapy called the ZAP-X Gyroscopic Radiosurgery platform, manufactured by ZAP Surgical Systems.

This advanced treatment is being offered by CCPSC, which is part of the American Hospital of Paris.

The ZAP-X system is claimed to deliver stereotactic radiosurgery (SRS) with precision, concentrating radiation on the tumour target while minimising damage to healthy brain tissue.

By providing a painless and outpatient treatment option, SRS offers outcomes comparable to or better than traditional surgeries.

Moreover, ZAP-X eliminates the need for shielded radiation treatment rooms and the use of radioactive isotopes, reducing costs.

CCPSC radiation oncologist Dr Bacem Belghith said: “Because of the significant percentage of cancer patients who develop brain metastases, it was imperative we support our radiation oncology program with a dedicated SRS solution such as ZAP-X.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

The vault-free design of the ZAP-X platform eliminates the requirement for expensive shielded treatment rooms.

CCPSC radiation oncologist Dr Alain Allaw said: “As ZAP-X is designed specifically for cranial radiosurgery it allows us to treat the most challenging cases with confidence.

“And unlike multi-purpose radiotherapy devices, ZAP-X provides patients with potentially lower healthy brain exposure to radiation, and thus enables greater flexibility for our clinical team to treat recurring brain metastases patients.”